Rallybio reports Q4 2021 net loss of $12.4M; cash $175.3M; pipeline updates on RLYB212 and RLYB116

Rallybio Corp

Net loss of $12.4M ($0.42 per share) for Q4 2021; full year net loss $47.0M ($1.84 per share).
Cash and cash equivalents of $175.3M as of December 31, 2021.
R&D expenses $6.1M in Q4 2021 ($26.9M FY); G&A $6.2M Q4 ($18.7M FY).
Phase 1b proof-of-concept for RLYB212 (FNAIT) to start Q2 2022; initial data expected Q3 2022.
Phase 1 study of RLYB116 (C5 inhibitor) initiated; single dose safety/PK/PD data expected 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.